Mathai Mammen, SVP, Research & Early Clin Development at THERAVANCE INC (THRX), sold 35,000 shares at $40.04 ($1.4M) on 2014-02-14, disclosed to the SEC on 2014-02-19.
Scheduled sale ($1.4M) by SVP, Research & Early Clin Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.26 | 30,400 | $1.2M | 86.6% |
| 2 | $40.04 | 4,600 | $184K | 13.4% |
| Total | $39.36 avg | 35,000 | $1.4M | 100% |
| Filing → |
| THRX | SELL | 2013-05-02 | $236K | — | Filing → |
| THRX | SELL | 2013-02-22 | $155K | — | Filing → |
| THRX | SELL | 2012-11-06 | $150K | — | Filing → |